Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) passed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $3.09 and traded as high as $3.32. SAB Biotherapeutics shares last traded at $3.20, with a volume of 886,269 shares changing hands.
Wall Street Analyst Weigh In
Several research analysts have issued reports on SABS shares. Wall Street Zen raised SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 10th. Weiss Ratings upgraded shares of SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, SAB Biotherapeutics has an average rating of “Moderate Buy” and a consensus target price of $12.00.
Get Our Latest Research Report on SAB Biotherapeutics
SAB Biotherapeutics Stock Performance
The stock has a 50 day moving average of $3.09 and a 200 day moving average of $3.62. The company has a quick ratio of 7.28, a current ratio of 7.28 and a debt-to-equity ratio of 0.01. The firm has a market cap of $288.29 million, a price-to-earnings ratio of -2.41 and a beta of 0.67.
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03. As a group, analysts anticipate that SAB Biotherapeutics, Inc. will post -1.13 EPS for the current fiscal year.
Hedge Funds Weigh In On SAB Biotherapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Perceptive Advisors LLC increased its stake in SAB Biotherapeutics by 700.8% in the first quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock valued at $24,634,000 after purchasing an additional 5,628,533 shares in the last quarter. Seven Fleet Capital Management LP lifted its position in shares of SAB Biotherapeutics by 47.2% during the 2nd quarter. Seven Fleet Capital Management LP now owns 736,077 shares of the company’s stock worth $2,871,000 after buying an additional 236,077 shares in the last quarter. Affinity Asset Advisors LLC bought a new position in SAB Biotherapeutics during the first quarter valued at about $2,202,000. Monashee Investment Management LLC bought a new position in SAB Biotherapeutics during the first quarter valued at $1,915,000. Finally, DV Trading LLC purchased a new position in shares of SAB Biotherapeutics in the first quarter worth about $1,532,000. Institutional investors and hedge funds own 7.82% of the company’s stock.
About SAB Biotherapeutics
SAB Biotherapeutics is a biotechnology company developing antibody-based medicines for autoimmune and infectious diseases. Its platform uses genetically engineered cattle to produce fully human polyclonal antibodies, which the company evaluates as potential treatments. The company’s pipeline has included SAB-142, an investigational therapy being developed for type 1 diabetes. Earlier programs included antibody candidates targeting infectious diseases, such as influenza and COVID-19. SAB Biotherapeutics was founded in 2014 and is based in Sioux Falls, South Dakota.
See Also
- Five stocks we like better than SAB Biotherapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
